65,437 trials
Common Cold
Primary: Number of Days With at Least Moderate (i.e. Moderate or Severe) Common Cold Symptoms. — 7.6; 9.5 Number of days — p=0.023
Graft Rejection · Kidney Disease
Primary: Number of Patients With Renal Allograft Rejection — 5 participant
HIV Infections
Primary: Proportion of Patients Without Failure of Strategy From Week 0 to Week 72 — 73; 55 Pourcentage — p=0.025
Dysmenorrhea
Primary: Percentage of Intervention Uses That Resulted in at Least 1 Point Decrease in Pain and Requiring no Rescue Medication Using the Modified Melzack-McGill Scale Using a…
Rheumatoid Arthritis
Primary: American College of Rheumatology 20 Response (ACR20) at 6 Months — 23; 26; 23; 21 Participants
Arthroplasty, Replacement, Knee · Blood Transfusion, Autologous · Blood Transfusion
Primary: Frequency of Natural Killer Cells as Measured With Flow Cytometry. — 2.98; 2.26 total number of cells * 10^5/mL
Myopia
Primary: Comfort After Insertion — 8.7; 7.7 Scale 1-10
Dysmenorrhea
Primary: Change From Baseline in Total Dysmenorrheal Score at Final Evaluation — -2.5; -2.1; -1.9; -1.0 scores on a scale — p=<0.001
Meningococcal Meningitis · Human Papillomavirus Infection · Pertussis
Primary: Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Seroresponse — 80; 82; 87; 83 Percentage of participants
Irritable Bowel Syndrome
Primary: Response of Overall IBS Symptom Relief - 50% Rule — 79; 61; 61; 78 Participants
Adolescent Immunizations · Preventive Care
Primary: Receipt of Adolescent Immunization at End of Study Period (Tdap, Menactra, HPV) — 1091; 885; 1783; 1367 participants
Myopia
Primary: Comfort at End of Day — 6.5; 6.9 Scale of 1-10
Autism · Autism Spectrum Disorder (ASD)
Primary: Change in Diet Groups Scores on One of Several Measures Used Against Pre-defined Statistical Thresholds as Evidence of Improvement. — -0.16715; 0.08235; -0.16176…
Tobacco Dependence
Primary: Treatment-Related Adverse Events — 25.6; 39.1; 21.3; 0 Percentage of Participants
Cystic Fibrosis · Pancreatic Exocrine Insufficiency
Primary: Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE) — 9 Participants